Zolpidem reduces hippocampal neuronal activity in freely behaving mice: A large scale calcium imaging study with miniaturized fluorescence microscope

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Berdyyeva, Tamara ^a   Otte, Stephani ^b   Aluisio, Leah ^a   Ziv, Yaniv ^b   Burns, Laurie D ^b   Dugovic, Christine ^a   Yun, Sujin ^a   Ghosh, Kunal K ^b   Schnitzer, Mark J ^b   Lovenberg, Timothy ^a   Bonaventure, Pascal ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Inscopix   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; NEURONAL CALCIUM SENSOR; PARVOVIRUS VECTOR; PROTEIN GCAMP3; UNCLASSIFIED DRUG; ZOLPIDEM; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; PYRIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL ACTIVITY; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; FLUORESCENCE MICROSCOPE; HIPPOCAMPAL CA1 REGION; LATENT PERIOD; LOCOMOTION; MALE; MEMORY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; SLEEP; ANIMAL; CYTOLOGY; DRUG EFFECTS; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; METABOLISM; MOLECULAR IMAGING; PHYSIOLOGY; PROCEDURES;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; CA1 REGION, HIPPOCAMPAL; CALCIUM; GABA-A RECEPTOR AGONISTS; LOCOMOTION; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; OPTICAL IMAGING; PYRAMIDAL CELLS; PYRIDINES;

EID: 84910650150     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112068     Document Type: Article

References (142)

1. Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Working Group (16 Sep 2013). Interim Report. Available: http://www.nih.gov/science/brain/09162013-Interim%20Report-Final%20Composite.pdf.
2. Alivisatos AP, Andrews AM, Boyden E.S., Chun M., Church GM et al. (2013) Nanotools for neuroscience and brain activity mapping. ACS Nano. 2013 Mar 26; 7(3): 1850-66. doi:10.1021/nn4012847.
3. Deisseroth K, Schnitzer M.J. (2013) Engineering approaches to illuminating brain structure and dynamics. Neuron. 2013 Oct 30; 80(3): 568-77. doi:10.1016/j.neuron.2013.10.032.
4. Knöpfel T (2012) Genetically encoded optical indicators for the analysis of neuronal circuits. Nat Rev Neurosci. 2012 Oct; 13(10): 687-700. doi:10.1038/nrn3293.
5. Ghosh KK, Burns LD, Cocker E.D., Nimmerjahn A., Ziv Y et al. (2011) Miniaturized integration of a fluorescence microscope. Nat Methods. 8(10): 871-8.
6. Mukamel EA, Nimmerjahn A, Schnitzer M.J. (2009) Automated analysis of cellular signals from large-scale calcium imaging data. Neuron. 63(6): 747-60.
7. Ziv Y, Burns LD, Cocker E.D., Hamel EO, Ghosh KK et al. (2013) Long-term dynamics of CA1 hippocampal place codes. Nature Neuroscience. 16(3): 264-6.
8. Greenblatt DJ, Roth T. (2012) Zolpidem for insomnia. Expert Opin Pharmacother. 2012 Apr; 13(6): 879-93. doi:10.1517/14656566.2012.667074.
9. Sanger DJ (2004) The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs. 2004; 18 Suppl 1: 9-15; discussion 41, 43-5.
10. Richey SM, Krystal A.D. (2011) Pharmacological advances in the treatment of insomnia. Curr Pharm Des. 2011; 17(15): 1471-5.
11. Vlainić J, Pericić D (2010) Zolpidem is a potent anticonvulsant in adult and aged mice. Brain Res. 2010 Jan 15; 1310: 181-8. doi:10.1016/j.brainres.2009.11.018.
12. Pericić D, Vlainić J, Strac DS (2008) Sedative and anticonvulsant effects of zolpidem in adult and aged mice. J Neural Transm. 2008 Jun; 11 5(6): 795-802. doi:10.1007/s00702-008-0020-0.
13. Zanin KA, Patti CL, Sanday L, Fernandes-Santos L, Oliveira LC et al. (2013) Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task. Psychopharmacology (Berl). 2013 Apr; 226(3): 459-74. doi:10.1007/s00213-012-2756-3.
14. Zahreddine N, Richa S. (2013) Non-Antidepressant Treatment of Generalized Anxiety Disorder. Curr Clin Pharmacol. 2013 Feb 4.
15. Rowlett JK, Kehne JH, Sprenger K.J., Maynard G.D. (2011) Emergence of anticonflict effects of zolpidem in rhesus monkeys following extended post-injection intervals. Psychopharmacology (Berl). 2011 Apr; 214(4): 855-62. doi:10.1007/s00213-010-2093-3.
16. Huang MP, Radadia K, Macone B.W., Auerbach SH, Datta S. (2010) Effects of eszopiclone and zolpidem on sleep-wake behavior, anxiety-like behavior and contextual memory in rats. Behav Brain Res. 2010 Jun 26; 210(1): 54-66. doi:10.1016/j.bbr.2010.02.018.
17. Fava M, Asnis GM, Shrivastava R, Lydiard B., Bastani B et al. (2009) Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009 Jun; 29(3): 222-30. doi:10.1097/JCP.0b013e3181a390ba.
18. Tashjian RZ, Banerjee R, Bradley M.P., Alford W., Fadale P.D. (2006) Zolpidem reduces postoperative pain, fatigue, and narcotic consumption following knee arthroscopy: a prospective randomized placebo-controlled double-blinded study. J Knee Surg. 2006 Apr; 1 9(2): 105-11.
19. Pick CG, Chernes Y, Rigai T., Rice KC, Schreiber S. (2005) The antinociceptive effect of zolpidem and zopiclone in mice. Pharmacol Biochem Behav. 2005 Jul; 81(3): 417-23.
20. Rode F, Jensen DG, Blackburn-Munro G, Bjerrum O.J. (2005) Centrally-mediated antinociceptive actions of GABA(A) receptor agonists in the rat spared nerve injury model of neuropathic pain. Eur J Pharmacol. 2005 Jun 1; 516(2): 131-8.
21. Du B, Shan A, Zhang Y., Zhong X, Chen D et al. (2014) Zolpidem arouses patients in vegetative state after brain injury: quantitative evaluation and indications. Am J Med Sci. 2014 Mar; 347(3): 178-82. doi:10.1097/MAJ.0b013e318287c79c.
22. Pistoia F, Sarà M, Sacco S, Franceschini M, Carolei A (2013) Silencing The Brain May Be Better Than Stimulating it. The GABA Effect. Curr Pharm Des. 2013 Sep 10.
23. Machado C, Estévez M, Rodríguez R, Pérez-Nellar J, Chinchilla M et al. (2013) Zolpidem Arousing Effect In Persistent Vegetative State Patients: Autonomic, Eeg And Behavioral Assessment. Curr Pharm Des. 2013 Sep 10.
24. Snyman N, Egan JR, London K, Howman-Giles R, Gill D et al. (2010) Zolpidem for persistent vegetative state-a placebo-controlled trial in pediatrics. Neuropediatrics. 2010 Oct; 41(5): 223-7. doi:10.1055/s-0030-1269893.
25. Thonnard M, Gosseries O, Demertzi A., Lugo Z, Vanhaudenhuyse A et al. (2014) Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study. Funct Neurol. 2014 Jan 11: 1-6. doi:10.11138/FNeur/2013.28.4.259.
26. Mura E, Pistoia F, Sarà M, Sacco S, Carolei A et al. (2013) Pharmacological modulation of the state of awareness in patients with Disorders of Consciousness: an Overview. Curr Pharm Des. 2013 Sep 11.
27. Whyte J, Myers R. (2009) Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil. 2009 May; 88(5): 410-8. doi:10.1097/PHM.0b013e3181a0e3a0.
28. Fitzgerald AC, Wright BT, Heldt S.A. (2014) The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors. Psychopharmacology (Berl). 2014 May; 231(9): 1865-96. doi:10.1007/s00213-014-3457-x.
29. Diezi L, Renard D, Rothuizen L.E., Livio F. (2014) [Pharmacovigilance update]. Rev Med Suisse. 2014 Jan 15; 10(412-413): 119-22.
30. Kuehn BM (2013) FDA warning: Driving may be impaired the morning following sleeping pill use. JAMA. 2013 Feb 20; 309(7): 645-6. doi:10.1001/jama.2013.323.
31. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Available: http://www.fda.gov/drugs/drugsafety/ucm334033.htm.
32. Perouansky M, Pearce R.A. (2011) How we recall (or don't): the hippocampal memory machine and anesthetic amnesia. Can J Anaesth. 2011 Feb; 58(2): 157-66. doi:10.1007/s12630-010-9417-y.
33. Cope DW, Halbsguth C, Karayannis T., Wulff P, Ferraguti F et al. (2005) Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation. Eur J Neurosci. 2005 Jun; 21(11): 3002-16.
34. Higashima M, Kinoshita H, Koshino Y. (1998) Differences in the effects of zolpidem and diazepam on recurrent inhibition and long-term potentiation in rat hippocampal slices. Neurosci Lett. 1998 Apr 3; 245(2): 77-80.
35. Goldstein PA, Elsen FP, Ying S.W., Ferguson C., Homanics GE et al. (2002) Prolongation of hippocampal miniature inhibitory postsynaptic currents in mice lacking the GABA(A) receptor alpha1 subunit. J Neurophysiol. 2002 Dec; 88(6): 3208-17.
36. Liang J, Cagetti E, Olsen R.W., Spigelman I. (2004) Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence. J Pharmacol Exp Ther. 2004 Sep; 310(3): 1234-45.
37. Manuel NA, Davies CH (1998) Pharmacological modulation of GABA(A) receptor-mediated postsynaptic potentials in the CA1 region of the rat hippocampus. Br J Pharmacol. 1998 Dec; 125(7): 1529-42.
38. Mokler DJ, Galler JR, Luebke J.I. (2001) Development and modulation of GABA(A) receptor-mediated neurotransmission in the CA1 region of prenatally protein malnourished rats. Nutr Neurosci. 2001; 4(2): 109-19.
39. Rovira C, Ben-Ari Y (1993) Developmental study of benzodiazepine effects on monosynaptic GABAA-mediated IPSPs of rat hippocampal neurons. J Neur-ophysiol. 1993 Sep; 70(3): 1076-85.
40. Zeng XJ, Tietz E.I. (1999) Benzodiazepine tolerance at GABAergic synapses on hippocampal CA1 pyramidal cells. Synapse. 1999 Mar 15; 31(4): 263-77.
41. Brown RE, Basheer R, McKenna J.T., Strecker RE, McCarley R.W. (2012) Control of sleep and wakefulness. Physiol Rev. 2012 Jul; 92(3): 1087-187. doi:10.1152/physrev.00032.2011.
42. Harrison NL (2007) Mechanisms of sleep induction by GABA(A) receptor agonists. J Clin Psychiatry. 2007; 68 Suppl 5: 6-12.
43. Shelton J, Bonaventure P, Li X., Yun S, Lovenberg T et al. (2009) 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. Neuropharmacology. 2009 Feb; 56(2): 448-54. doi:10.1016/j.neuropharm.2008.09.014.
44. Dugovic C, Shelton JE, Aluisio L.E., Fraser IC, Jiang X et al TW (2009) Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther. 2009 Jul; 330(1): 142-51. doi:10.1124/jpet.109.152009.
45. Dugovic C, Shelton JE, Yun S, Bonaventure P., Shireman BT et al. (2014) Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci. 2014 Feb 14; 8: 28. doi:10.3389/fnins.2014.00028.
46. Barretto RP, Ko TH, Jung J.C., Wang TJ, Capps G et al. (2011) Time-lapse imaging of disease progression in deep brain areas using fluorescence microendoscopy. Nat Med. 17(2): 223-8.
47. McNaughton BL, Barnes CA, O'Keefe J (1983) The contributions of position, direction, and velocity to single unit activity in the hippocampus of freely-moving rats. Exp Brain Res. 1983; 52(1): 41-9.
48. Ramirez AD, Gotter AL, Fox S.V., Tannenbaum PL, Yao L et al. (2013) Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci. 2013; 7: 254. doi:10.3389/fnins.2013.00254.
49. Behrendt RP (2013) Hippocampus and consciousness. Rev Neurosci. 2013; 24(3): 239-66. doi:10.1515/revneuro-2012-0088.
50. Burgess N, Maguire EA, O'Keefe J (2002) The human hippocampus and spatial and episodic memory. Neuron. 2002 Aug 15; 35(4): 625-41.
51. Eichenbaum, H; Cohen NJ (1993). Memory, Amnesia, and the Hippocampal System. MIT Press.
52. Eichenbaum H (2004) Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron. 2004 Sep 30; 44(1): 109-20.
53. Henke K (2010) A model for memory systems based on processing modes rather than consciousness. Nat Rev Neurosci. 2010 Jul; 11(7): 523-32. doi:10.1038/nrn2850.
54. Henson RN, Gagnepain P. (2010) Predictive, interactive multiple memory systems. Hippocampus. 2010 Nov; 20(11): 1315-26. doi:10.1002/hipo.20857.
55. Moser MB, Moser E.I. (1998) Functional differentiation in the hippocampus. Hippocampus. 1998; 8(6): 608-19.
56. Colgin LL, Moser EI, Moser M.B. (2008) Understanding memory through hippocampal remapping. Trends Neurosci. 2008 Sep; 31(9): 469-77. doi:10.1016/j.tins.2008.06.008.
57. Packard MG. (2009) Anxiety, cognition, and habit: a multiple memory systems perspective. Brain Res. 2009 Oct 13; 1293: 121-8. doi:10.1016/j.brainres.2009.03.029.
58. Schacter DL (2012) Constructive memory: past and future. Dialogues Clin Neurosci. 2012 Mar; 14(1): 7-18.
59. Squire, LR; Schacter DL (2002). The Neuropsychology of Memory. Guilford Press.
60. Ahrens MB, Orger MB, Robson D.N., Li JM, Keller P.J. (2103) Whole-brain functional imaging at cellular resolution using light-sheet microscopy. Nat Methods. 2013 May; 10(5): 413-20. doi:10.1038/nmeth.2434.
61. Jessen SB, Brazhe A, Lind B.L., Mathiesen C., Thomsen K et al. (2014) GABAA Receptor-Mediated Bidirectional Control of Synaptic Activity, Intracellular Ca2+, Cerebral Blood Flow, and Oxygen Consumption in Mouse Somato-sensory Cortex In Vivo. Cereb Cortex. 2014 Mar 31. [Epub ahead of print].
62. Ujfalussy B, Kiss T, Orbán G, Hoffmann W.E., Erdi P et al. (2007) Pharmacological and computational analysis of alpha-subunit preferential GABA(A) positive allosteric modulators on the rat septo-hippocampal activity. Neuropharmacology. 2007 Mar; 52(3): 733-43.
63. Taketo M, Yoshioka T. (2000) Developmental change of GABA(A) receptor-mediated current in rat hippocampus. 2000; 96(3): 507-14.
64. Chen G, King JA, Burgess N, O'Keefe J (2013) How vision and movement combine in the hippocampal place code. Proc Natl Acad Sci U S A. 2013 Jan 2; 110(1): 378-83. doi:10.1073/pnas.1215834110.
65. Foster TC, Castro CA, McNaughton B.L. (1989) Spatial selectivity of rat hippocampal neurons: dependence on preparedness for movement. Science. 1989 Jun 30; 244 (4912): 1580-2.
66. Kemere C, Carr MF, Karlsson M.P., Frank L.M. (2013) Rapid and continuous modulation of hippocampal network state during exploration of new places. PLoS One. 2013 Sep 2; 8(9): e73114. doi:10.1371/journal.pone.0073114.
67. Mizumori SJ, Garcia PA, Raja M.A., Volpe B.T. (1995) Spatial- and locomotion-related neural representation in rat hippocampus following long-term survival from ischemia. Behav Neurosci. 1995 Dec; 109(6): 1081-94.
68. Crestani F, Martin JR, Möhler H, Rudolph U. (2000) Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol. 2000 Dec; 131(7): 1251-4.
69. Depoortere H, Zivkovic B, Lloyd K.G., Sanger DJ, Perrault G et al. (1986) Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther. 1986 May; 237(2): 649-58.
70. Murphy HM, Ihekoronze C, Wideman C.H. (2011) Zolpidem-induced changes in activity, metabolism, and anxiety in rats. Pharmacol Biochem Behav. 2011 Mar; 98(1): 81-6. doi:10.1016/j.pbb.2010.12.012.
71. Sanger DJ, Morel E, Perrault G. (1996) Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol. 1996 Oct 10; 313(1-2): 35-42.
72. Vlainić J, Pericić D (2009) Effects of acute and repeated zolpidem treatment on pentylenetetrazole-induced seizure threshold and on locomotor activity: comparison with diazepam. Europharmacology. 2009 Jun; 56(8): 1124-30. doi:10.1016/j.neuropharm.2009.03.010.
73. Berlin I, Warot D, Hergueta T., Molinier P, Bagot C et al. (1993) Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol. 1993 Apr; 13(2): 100-6.
74. Danjou P, Paty I, Fruncillo R., Worthington P, Unruh M et al. (1999) A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol. 1999 Sep; 48(3): 367-74.
75. Farber RH, Burke P.J. (2008) Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers. Curr Med Res Opin. 2008 Mar; 24(3): 837-46. doi:10.1185/0300799086273327.
76. Leufkens TR, Lund JS, Vermeeren A. (2009) Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J Sleep Res. 2009 Dec; 18(4): 387-96. doi:10.1111/j.1365-2869.2009.00746.x.
77. Lucchesi LM, Braga NI, Manzano G.M., Pompéia S, Tufik S. (2005) Acute neurophysiological effects of the hypnotic zolpidem in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2005 May; 29(4): 557-64.
78. Meskali M, Berthelon C, Marie S., Denise P, Bocca M.L. (2009) Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study. Psychopharmacology (Berl). 2009 Dec; 207(3): 461-7. doi:10.1007/s00213-009-1677-2.
79. Otmani S, Demazières A, Staner C., Jacob N, Nir T et al. (2008) Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008 Dec; 23(8): 693-705. doi:10.1002/hup.980.
80. Verster JC, Volkerts ER, Olivier B, Johnson W., Liddicoat L. (2007) Zolpidem and traffic safety - the importance of treatment compliance. Curr Drug Saf. 2007 Sep; 2(3): 220-6.
81. Evans SM, Funderburk FR, Griffiths R.R. (1990) Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther. 1990 Dec; 255(3): 1246-55.
82. Vermeeren A (2004) Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004; 18(5): 297-328.
83. Vermeeren A, Vuurman EF, Leufkens T.R., Van Leeuwen CJ, Van Oers AC et al. (2014) Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use. Sleep. 2014 Mar 1; 37(3): 489-96. doi:10.5665/sleep.3482.
84. Gunja N (2013) In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol. 2013 Jun; 9(2): 163-71. doi:10.1007/s13181-013-0294-y.
85. Di Lazzaro V., Pilato F, Dileone M., Ranieri F, Ricci V et al. (2006) GABAA receptor subtype specific enhancement of inhibition in human motor cortex. J Physiol. 2006 Sep 15; 575(Pt 3): 721-6.
86. Mohammadi B, Krampfl K, Petri S., Bogdanova D, Kossev A et al. (2006) Selective and nonselective benzodiazepine agonists have different effects on motor cortex excitability. Muscle Nerve. 2006 Jun; 33(6): 778-84.
87. Abe K (2008) Zolpidem therapy for movement disorders. Recent Pat CNS Drug Discov. 2008 Jan; 3(1): 55-60.
88. Nazar M, Siemiatkowski M, Członkowska A, Sienkiewicz-Jarosz H, Płaźnik A (1999) The role of the hippocampus and 5-HT/GABA interaction in the central effects of benzodiazepine receptor ligands. J Neural Transm. 1999; 106(5-6): 369-81.
89. Doble A (1999) New insights into the mechanism of action of hypnotics. J Psychopharmacol. 1999; 13(4 Suppl 1): S11-20.
90. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004; 43(4): 227-38.
91. Graham D, Faure C, Besnard F., Langer S.Z. (1996). Pharmacological profile of benzodiazepine site ligands with recombinant GABAA receptor subtypes. Eur. Neuropsychopharmacol. 6, 119-125. 10.1016/0924-977X(95)00072-W.
92. Kostowski W (1995) Recent advances in the GABA-A-benzodiazepine receptor pharmacology. Pol J Pharmacol. 1995 May-Jun; 47(3): 237-46.
93. Sieghart W, Sperk G. (2002). Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr. Top. Med. Chem. 2, 795-816. 10.2174/1568026023393507.
94. Da Settimo F., Taliani S, Trincavelli M.L., Montali M., Martini C. (2007) GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem. 2007; 14(25): 2680-701.
95. Rudolph U, Crestani F, Benke D., Brünig I, Benson JA et al. (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999 Oct 21; 401 (6755): 796-800.
96. Erratum in: Nature 2000 Apr 6; 404 (6778): 629.
97. McKernan RM, Rosahl TW, Reynolds D.S., Sur C., Wafford KA et al. (2000) Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000 Jun; 3(6): 587-92.
98. Pirker S, Schwarzer C, Wieselthaler A., Sieghart W, Sperk G. (2000) GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience. 2000; 101(4): 815-50.
99. Heldt SA, Ressler K.J. (2007) Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization. Neuroscience. 2007 Dec 5; 150(2): 370-85.
100. Hörtnagl H., Tasan RO, Wieselthaler A, Kirchmair E., Sieghart W et al. (2013) Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience. 2013 Apr 16; 236: 345-72. doi:10.1016/j.neuroscience.2013.01.008.
101. Kasugai Y, Swinny JD, Roberts J.D., Dalezios Y., Fukazawa Y et al. (2010) Quantitative localisation of synaptic and extrasynaptic GABAA receptor subunits on hippocampal pyramidal cells by freeze-fracture replica immuno-labelling. Eur J Neurosci. 2010 Dec; 32(11): 1868-88. doi:10.1111/j.1460-9568.2010.07473.x.
102. Lee V, Maguire J. (2014) The impact of tonic GABAA receptor-mediated inhibition on neuronal excitability varies across brain region and cell type. Front Neural Circuits. 2014 Feb 3; 8: 3. doi:10.3389/fncir.2014.00003.
103. Panzanelli P, Gunn BG, Schlatter M.C., Benke D., Tyagarajan SK et al. (2011) Distinct mechanisms regulate GABAA receptor and gephyrin clustering at perisomatic and axo-axonic synapses on CA1 pyramidal cells. J Physiol. 2011 Oct 15; 589(Pt 20): 4959-80. doi:10.1113/jphysiol.2011.216028.
104. Saari TI, Uusi-Oukari M, Ahonen J., Olkkola K.T. (2011) Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev. 2011 Mar; 63(1): 243-67. doi:10.1124/pr.110.002717.
105. Sperk G, Schwarzer C, Tsunashima K., Fuchs K, Sieghart W. (1997) GABA(A) receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits. Neuroscience. 1997 Oct; 80(4): 987-1000.
106. Vargas-Caballero M., Martin LJ, Salter M.W., Orser BA, Paulsen O. (2010) alpha5 Subunit-containing GABA(A) receptors mediate a slowly decaying inhibitory synaptic current in CA1 pyramidal neurons following Schaffer collateral activation. Neuropharmacology. 2010 Mar; 58(3): 668-75. doi:10.1016/j.neuropharm.2009.11.005.
107. Perrais D, Ropert N. (1999) Effect of zolpidem on miniature IPSCs and occupancy of postsynaptic GABAA receptors in central synapses. J Neurosci. 1999 Jan 15; 19(2): 578-88.
108. Tietz EI, Kapur J, Macdonald R.L. (1999) Functional GABAA receptor heterogeneity of acutely dissociated hippocampal CA1 pyramidal cells. J Neurophysiol. 1999 Apr; 81(4): 1575-86.
109. Buibas M, Silva G.A. (2011) A framework for simulating and estimating the state and functional topology of complex dynamic geometric networks. Neural Comput. 2011 Jan; 23(1): 183-214. doi:10.1162/NECO-a-00065.
110. Chen TW, Wardill TJ, Sun Y, Pulver S.R., Renninger SL et al. (2013) Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature. 2013 Jul 18; 499 (7458): 295-300. doi:10.1038/nature12354.
111. Ding J, Luo AF, Hu L, Wang D., Shao F. (2014) Structural basis of the ultrasensitive calcium indicator GCaMP6. Sci China Life Sci. 2014 Mar; 57(3): 269-74. doi:10.1007/s11427-013-4599-5.
112. Brickley SG, Mody I. (2012) Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron. 2012 Jan 12; 73(1): 23-34. doi:10.1016/j.neuron.2011.12.012.
113. Fernandez FR, White J.A. (2010) Gain control in CA1 pyramidal cells using changes in somatic conductance. J Neurosci. 2010 Jan 6; 30(1): 230-41. doi:10.1523/JNEUROSCI.3995-09.2010.
114. Groen MR, Paulsen O, Perez-Garci E, Nevian T., Wortel J et al. (2014) Development of dendritic tonic GABAergic inhibition regulates excitability and plasticity in CA1 pyramidal neurons. J Neurophysiol. 2014 Apr 23. [Epub ahead of print].
115. Héja L., Nyitrai G, Kékesi O, Dobolyi A., Szabó P et al. (2012) Astrocytes convert network excitation to tonic inhibition of neurons. BMC Biol. 2012 Mar 15; 10: 26. doi:10.1186/1741-7007-10-26.
116. Yeung JY, Canning KJ, Zhu G, Pennefather P., MacDonald JF et al. (2003) Tonically activated GABAA receptors in hippocampal neurons are high-affinity, low-conductance sensors for extracellular GABA. Mol Pharmacol. 2003 Jan; 63(1): 2-8.
117. Yoon BE, Jo S, Woo J., Lee JH, Kim T et al. (2011) The amount of astrocytic GABA positively correlates with the degree of tonic inhibition in hippocampal CA1 and cerebellum. Mol Brain. 2011 Nov 22; 4: 42. doi:10.1186/1756-6606-4-42.
118. Zheng F, Khanna S. (2001) Selective destruction of medial septal cholinergic neurons attenuates pyramidal cell suppression, but not excitation in dorsal hippocampus field CA1 induced by subcutaneous injection of formalin. Neuroscience. 2001; 103(4): 985-98.
119. Lindquist CE, Birnir B. (2006) Graded response to GABA by native extrasynaptic GABA receptors. J Neurochem. 2006 Jun; 97(5): 1349-56.
120. Semyanov A, Walker MC, Kullmann D.M. (2003) GABA uptake regulates cortical excitability via cell type-specific tonic inhibition. Nat Neurosci. 2003 May; 6(5): 484-90.
121. Alexandre C, Dordal A, Aixendri R., Guzman A, Hamon M et al. (2008) Sleep-stabilizing effects of E-6199, compared to zopiclone, zolpidem and THIP in mice. Sleep. 2008 Feb; 31(2): 259-70.
122. Anaclet C, Zhang M, Zhao C., Buda C, Seugnet L et al. (2012) Effects of GF-015535-00, a novel α1 GABA A receptor ligand, on the sleep-wake cycle in mice, with reference to zolpidem. Sleep. 2012 Jan 1; 35(1): 103-11. doi:10.5665/sleep.1596.
123. Kopp C, Rudolph U, Tobler I. (2004) Sleep EEG changes after zolpidem in mice. Neuroreport. 2004 Oct 5; 15(14): 2299-302.
124. Xu Q, Xu XH, Qu W.M., Lazarus M., Urade Y et al. (2014) A mouse model mimicking human first night effect for the evaluation of hypnotics. Pharmacol Biochem Behav. 2014 Jan; 116: 129-36. doi:10.1016/j.pbb.2013.11.029.
125. Vyazovskiy VV, Harris K.D. (2013) Sleep and the single neuron: the role of global slow oscillations in individual cell rest. Nat Rev Neurosci. 2013 Jun; 14(6): 443-51. doi:10.1038/nrn3494.
126. Crunelli V, Hughes S.W. (2010) The slow (,1 Hz) rhythm of non-REM sleep: a dialogue between three cardinal oscillators. Nat Neurosci. 2010 Jan; 13(1): 9-17. doi:1.1038/nn.2445.
127. Ji D, Wilson M.A. (2007) Coordinated memory replay in the visual cortex and hippocampus during sleep. Nat. Neurosci. 2007; 10: 100-107.
128. Inostroza M, Born J. (2013) Sleep for preserving and transforming episodic memory. Annu Rev Neurosci. 2013 Jul 8; 36: 79-102. doi:10.1146/annurev-neuro-062012-170429.
129. Isomura Y, Sirota A, Ozen S., Montgomery S, Mizuseki K et al. (2006) Integration and segregation of activity in entorhinal-hippocampal subregions by neocortical slow oscillations. Neuron. 2006 Dec 7; 52(5): 871-82.
130. Vyazovskiy VV, Cirelli C, Tononi G. (2011) Electrophysiological correlates of sleep homeostasis in freely behaving rats. Prog Brain Res. 2011; 193: 17-38. doi:10.1016/B978-0-444-53839-0.00002-8.
131. Lundahl J, Deacon S, Maurice D., Staner L. (2012) EEG spectral power density profiles during NREM sleep for gaboxadol and zolpidem in patients with primary insomnia. J Psychopharmacol. 2012 Aug; 26(8): 1081-7. doi:10.1177/0269881111424457.
132. Monti JM, Alvariño F, Monti D. (2000) Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia. Sleep. 2000 Dec 15; 23(8): 1075-84.
133. Benoit O, Bouard G, Payan C., Borderies P, Prado J. (1994) Effect of a single dose (10 mg) of zolpidem on visual and spectral analysis of sleep in young poor sleepers. Psychopharmacology (Berl). 1994 Nov; 116(3): 297-303.
134. Inagaki T, Miyaoka T, Tsuji S., Inami Y, Nishida A et al. (2010) Adverse reactions to zolpidem: case reports and a review of the literature. Prim Care Companion J Clin Psychiatry. 2010; 12(6). pii: PCC.09r00849. doi:10.4088/PCC.09r00849bro.
135. Isawa S, Suzuki M, Uchiumi M., Murasaki M. (2000) The effect of zolpidem and zopiclone on memory. Nihon Shinkei Seishin Yakurigaku Zasshi. 2000 May; 20(2): 61-9.
136. Kleykamp BA, Griffiths RR, McCann U.D., Smith MT, Mintzer M.Z. (2012) Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use. Exp Clin Psychopharmacol. 2012 Feb; 20(1): 28-39. doi:10.1037/a0025237.
137. Lieberman JA (2007) Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry. 2007; 9(1): 25-31.
138. Mednick SC, McDevitt EA, Walsh J.K., Wamsley E., Paulus M et al. (2013) The critical role of sleep spindles in hippocampal-dependent memory: a pharmacology study. J Neurosci. 2013 Mar 6; 33(10): 4494-504. doi:10.1523/JNEUROSCI.3127-12.2013.
139. Uslaner JM, Tye SJ, Eddins D.M., Wang X., Fox SV et al. (2013) Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med. 2013 Apr 3; 5(179): 179ra44. doi:10.1126/scitranslmed.3005213.
140. Wilkinson CJ (1995) The acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. J Clin Psychiatry. 1995 Jul; 56(7): 309-18.
141. Zammit GK, Kramer J.A. (2001) The Importance of Residual Effects When Choosing a Hypnotic: The Unique Profile of Zaleplon. Prim Care Companion J Clin Psychiatry. 2001 Apr; 3(2): 53-60.
142. Ban TA (2006) The role of serendipity in drug discovery. Dialogues Clin Neurosci. Sep 2006; 8(3): 335-344.